Stem Cell Therapy for Pets - Teddy Before After
Amazing before and after footage of Teddy, an 11 year old dog who received stem cell therapy for his arthritis and received an unexpected benefit to his hear...
By: NewmanVets
See the original post:
Stem Cell Therapy for Pets - Teddy Before
Purtier Placenta - Live Stem Cell Therapy (English version)
By: Zoey Purtier
Originally posted here:
Purtier Placenta - Live Stem Cell Therapy (English version) - Video
[Purtier placenta] obama speech - Stem Cells research
pls call Riway Zoey @ +65 83613188 for more info (deer placenta)
By: Zoey Purtier
Read more:
[Purtier placenta] obama speech - Stem Cells research - Video
Stem Cell Therapy for Pets -- Taylor Before After
Amazing before and after footage of Taylor, a 7 year old dog who received stem cell therapy for arthritis in her hips, knees and ankles. For more information...
By: NewmanVets
See original here:
Stem Cell Therapy for Pets -- Taylor Before
When does a financially struggling
biotech company turn down a $20 million “forgivable loan?”
“The funding would have been in the
form of a forgivable loan, however, we have elected not to borrow
these funds from CIRM(the stem cell agency).”
“You may also recall that last
September, CIRM approved a separate application under the same
disease team program for Alzheimer's disease, which was also for up
to $20 million in the form of a loan. We remain in confidential
negotiations with CIRM regarding the terms and conditions that would
attach to this loan.”
Nakae: “Okay. Just 2 more questions.
I guess the first one, as it relates to CIRM.
In deciding to decline the funding for spinal cord yet continuing to
pursue the funding for Alzheimer's, is there a difference in what
you're getting from them in terms of potential terms and conditions
that allow you to proceed on one and not the other, or is it the fact
that you're already in human with -- in spine, and still very
preclinical with Alzheimer's?”
McGlynn: :”I think you're very
definitely -- you're getting at some important criteria when one
considers how to fund programs whether you use debt or equity,
etcetera. So I wouldn't disagree with anything that you've outlined
or surmised. But I just would pray your indulgence until we're
finished, the negotiations with CIRM, which are coming to a close and
we expect those to resolve pretty quickly with regards to the
Alzheimer's program. And then quite frankly, we can be way more
forthcoming and way more disclosive with regards not only to our
decisions, but to our thinking.”
When does a financially struggling
biotech company turn down a $20 million “forgivable loan?”
“The funding would have been in the
form of a forgivable loan, however, we have elected not to borrow
these funds from CIRM(the stem cell agency).”
“You may also recall that last
September, CIRM approved a separate application under the same
disease team program for Alzheimer's disease, which was also for up
to $20 million in the form of a loan. We remain in confidential
negotiations with CIRM regarding the terms and conditions that would
attach to this loan.”
Nakae: “Okay. Just 2 more questions.
I guess the first one, as it relates to CIRM.
In deciding to decline the funding for spinal cord yet continuing to
pursue the funding for Alzheimer's, is there a difference in what
you're getting from them in terms of potential terms and conditions
that allow you to proceed on one and not the other, or is it the fact
that you're already in human with -- in spine, and still very
preclinical with Alzheimer's?”
McGlynn: :”I think you're very
definitely -- you're getting at some important criteria when one
considers how to fund programs whether you use debt or equity,
etcetera. So I wouldn't disagree with anything that you've outlined
or surmised. But I just would pray your indulgence until we're
finished, the negotiations with CIRM, which are coming to a close and
we expect those to resolve pretty quickly with regards to the
Alzheimer's program. And then quite frankly, we can be way more
forthcoming and way more disclosive with regards not only to our
decisions, but to our thinking.”
Stem Cell Therapy Treatment for Muscular Dystrophy by Dr Alok Sharma, Mumbai, India.
Stem Cell Therapy Treatment for Muscular Dystrophy by Dr Alok Sharma, Mumbai, India. After Stem Cell Therapy 1. Could stand with calipers and walker (after 7...
By: neurogenbsi
More here:
Stem Cell Therapy Treatment for Muscular Dystrophy by Dr Alok Sharma, Mumbai, India. - Video
Stem Cell Therapy Treatment for Duchenne Muscular Dystrophy by Dr Alok Sharma, Mumbai, India.
Stem Cell Therapy Treatment for Duchenne Muscular Dystrophy by Dr Alok Sharma, Mumbai, India. After Stem Cell Therapy PT assessment: 1) In walking, whole foo...
By: neurogenbsi
See the rest here:
Stem Cell Therapy Treatment for Duchenne Muscular Dystrophy by Dr Alok Sharma, Mumbai, India. - Video
Stem cell therapy for AVN in India, Experience of patient from Canada
Avascular necrosis also known as osteonecrosis, aseptic necrosis, and ischemic bone necrosis. It is a disease resulting from the temporary or permanent loss ...
By: StemRx BioScience
Read this article:
Stem cell therapy for AVN in India, Experience of patient from Canada - Video
Stem Cell Therapy Treatment Improvements in Muscular Dystrophy by Dr Alok Sharma, Mumbai, India.
Stem Cell Therapy Treatment Improvements in Muscular Dystrophy by Dr Alok Sharma, Mumbai, India. After Stem Cell Therapy 1. Could stand with calipers and wal...
By: neurogenbsi
See the original post:
Stem Cell Therapy Treatment Improvements in Muscular Dystrophy by Dr Alok Sharma, Mumbai, India. - Video
Stem Cell Therapy Treatment for Spinal Cord Injury by Dr Alok Sharma, Mumbai, India.
Stem Cell Therapy Treatment for Spinal Cord Injury by Dr Alok Sharma, Mumbai, India. After Stem Cell Therapy 1. Ankle clonus/jerk in both legs has reduced. P...
By: neurogenbsi
Original post:
Stem Cell Therapy Treatment for Spinal Cord Injury by Dr Alok Sharma, Mumbai, India. - Video
Stem Cell Therapy Treatment for Cerebral Palsy by Dr Alok Sharma, Mumbai, India.
Stem Cell Therapy Treatment for Cerebral Palsy by Dr Alok Sharma, Mumbai, India. After Stem Cell Therapy PT assessment: 1) Speech has improved. Now he is abl...
By: neurogenbsi
Read the rest here:
Stem Cell Therapy Treatment for Cerebral Palsy by Dr Alok Sharma, Mumbai, India. - Video
ARAD, Israel, April 2, 2013 /PRNewswire/ --
Andain Inc. (ANDN) ("Andain" or the "Company"), a company engaged in commercializing novel technologies in biotech, medical and life sciences fields through its incubator program, today discussed and provided an update on its breakthrough, innovative stem cell therapy for treating and regenerating severely damaged muscle tissue.
Andain's innovative stem cell therapy technology rehabilitates and heals damaged muscle tissue by initiating regenerative myogenic cells (cardiac muscle), as well as striated muscle cells (skeletal muscle) growth in damaged tissue sites such as the myocardium (cardiac muscle) following an myocardial infarction (heart attack), limb pressure ulcers, and degenerative muscular diseases. The short term application is directed towards the treatment of patients with peripheral vascular disease, while the long term application is focused on the healing and regeneration of cardiac muscle following acute myocardial infarction or chronic heart failure.
Employing a patient's own cells (autologic transplantation), the Company's unique technology and process diverts the patient's own cells into specific targeted myogenic cells, which can then be inserted into the damaged tissue and accelerates the healing process. The administered myogenic or skeletal stem cells work as a network, acting in exactly the same way that the cells of skeletal and heart muscle tissue perform, and actually replenish the existing cells, thus strengthening the intended injured site following the transplantation process. This process can be utilized for different clinical pathologies as mentioned above and can also be utilized for patient using different donor as the source of the stem cells.
Our developed technology and protocols results in a promising safe regenerative therapy, without side effects, tissue rejection or the requirement of suppressive immunological treatment or malignant tumor hazard. Our technology also provides a simple, fast and safe treatment, overcoming technological difficulties associated with using other stem cell therapies sources such as embryonic, placenta, or umbilical cord blood cells that require cryogenic storage.
Andain's President and CEO Sam Elimelech, commented, "The field of stem cell therapeutics is in its early stages of growth as companies and researchers continue to uncover the vast potential and promising uses for them in the treatment and prevention of countless tissue injuries and diseases. We are in an excellent position to capitalize on the emergence of this new market. It is our belief that Orcell's cutting-edge technology and process is unique in regard to the fact that it allows for the safe and efficient directing of the patients own cells as into myogenic cells or striated muscle cells, thus eliminating the hazards associated with rejection and malignant tumors. Via our industrial incubator platform and expert scientific team, we look forward to helping Orcell commence their clinical trials later this year and make considerable progress of their technology and process closer to market."
Andain's incubator platform is currently undergoing with its stem cell technology a build-up of GLP (Good Laboratory Practice) production line as a preparation for the FDA approval stage with clinical trials scheduled for Q1 2014 at one of the foremost Heart centers in Israel under the direction of Professor Mickey Scheinowitz, one of Israel's leading scientists who gained vast experience in the understanding and treating of cardiovascular diseases.
ABOUT ANDAIN INC
Established in 2004 as a Nevada corporation with locations in Israel and the US, Andain (OTC: ANDN) commercializes novel technologies in the biotech, medical and life sciences fields, specializing in identifying technical innovations and providing a unique incubator/accelerator development and industrial platform. The company also offers technical know-how and business strategy expertise to commercialize new technologies and deliver shareholder value. For more information, please visit our website at http://www.andaininc.com.
FORWARD LOOKING STATEMENTS
Go here to see the original:
Andain Inc. Discusses and Provides Update on its Breakthrough Stem Cell Therapy for the Treatment and Regeneration of ...
By Tina G. Santos Philippine Daily Inquirer
MANILA, PhilippinesStem cell therapy at spa centers and salons? Watch out, government agents are coming.
Health Secretary Enrique Ona says no clinic or hospital in the Philippines can offer stem cell therapy without accreditation from the Department of Health (DOH).
Speaking to reporters last week, Ona noted that while many centers are advertising stem cell therapy treatment, none of them have the approval of the health department.
As of now we have not accredited any clinic or even hospital offering stem cell therapy yet, Ona said.
Admitting that the DOH doesnt have the police power to close down erring health centers, Ona said the department would coordinate with other governmental agencies like the Department of Trade and Industry (DTI) and local governments to prevent spas and salons from offering stem cell treatment.
We will issue a warning for them to stop [doing stem cell therapy]. But if they continue despite warnings from us, thats when we will move to close them down, Ona said.
Stem cell therapy and treatment, which are becoming popular here and abroad, are medical procedures that deal with ailments by replacing malignant cells with healthy cells.
Only medical doctors with the right training can perform stem cell treatment.
Cosmetic purposes
See the article here:
Spas, salons warned on stem cell therapy
A post entitled Funding for Personalized Medicine Research, dated January 31, 2012, provided information about the participation of the Cancer Stem Cell Consortium (CSCC) in the Large-Scale Applied Research Project Competition of Genome Canada, in collaboration with the first phase of the Personalized Medicine Signature Initiative of the Canadian Institutes of Health Research (CIHR).
On March 26, 2013, it was announced that 17 projects will be supported. A list of these project is available (PDF). One of the 17 projects is entitled "Innovative chemogenomic tools to improve outcome in acute myeloid leukemia". The Project leader is Guy Sauvageau of the Institute for Research in Immunology and Cancer (IRIC) at the Université de Montréal. The Project co-leader is Josée Hébert of the Centre de Recherche Hôpital Maisonneuve-Rosemont, Montréal. One of the aims of this project is to develop new models for tracking cancer stem cells that are left behind after a patient is treated.
Source:
http://cancerstemcellnews.blogspot.com/2013/03/more-about-funding-for-personalized.html
A post entitled Funding for Personalized Medicine Research, dated January 31, 2012, provided information about the participation of the Cancer Stem Cell Consortium (CSCC) in the Large-Scale Applied Research Project Competition of Genome Canada, in collaboration with the first phase of the Personalized Medicine Signature Initiative of the Canadian Institutes of Health Research (CIHR).
On March 26, 2013, it was announced that 17 projects will be supported. A list of these project is available (PDF). One of the 17 projects is entitled "Innovative chemogenomic tools to improve outcome in acute myeloid leukemia". The Project leader is Guy Sauvageau of the Institute for Research in Immunology and Cancer (IRIC) at the Université de Montréal. The Project co-leader is Josée Hébert of the Centre de Recherche Hôpital Maisonneuve-Rosemont, Montréal. One of the aims of this project is to develop new models for tracking cancer stem cells that are left behind after a patient is treated.
Source:
http://cancerstemcellnews.blogspot.com/2013/03/more-about-funding-for-personalized.html
Italian health officials are allowing a handful of patients to continue with a controversial stem cell therapy amid protests from scientists that the treatments are unproven and unsafe.
The Stamina Foundation has been administering the therapy at the public hospital Spedali Civili of Brescia to people with a range of degenerative diseases. Their approach is based on mesenchymal stem cells, derived from bone marrow, which can become mature bone and connective tissue.
In 2011 the hospital agreed to host the research and assist with cell extraction and patient treatments, stirring protests from the medical community. "The hospital is not even listed among the 13 Italian authorised stem cell factories," says Michele de Luca, director and gene therapy programme coordinator at the Centre for Regenerative Medicine in Modena. After an inspection in 2012, Italian drug regulator AIFA ordered an immediate halt to Stamina's stem cell treatments at the hospital.
The AIFA report says the Stamina Foundation's treatment did not follow Italy's official path required for clinical approval. So far no scientific publications describing its effectiveness are available.
But the halt sparked protests among patients' families who believed the treatment was working. Some appealed to the courts, and as a result a few patients were allowed to go ahead with the therapy. On 15 March, a group of 13 Italian stem cell researchers published an open letter to the country's Minister of Health, Renato Balduzzi, asking him to shut down all of the Stamina Foundation's treatments at the hospital.
Instead Balduzzi signed a bill last week authorising the foundation to continue treatments in patients who had already begun the regime unless they are experiencing serious side effects.
If you would like to reuse any content from New Scientist, either in print or online, please contact the syndication department first for permission. New Scientist does not own rights to photos, but there are a variety of licensing options available for use of articles and graphics we own the copyright to.
Only subscribers may leave comments on this article. Please log in.
Only personal subscribers may leave comments on this article
Subscribe now to comment.
Go here to read the rest:
Italy pushes on with controversial stem cell therapy
Albany, NY (PRWEB) March 29, 2013
GBI Research, the leading business intelligence provider, has released its latest research Stem Cell Therapy Market in Asia-Pacific to 2018 Commercialization Supported by Favorable Government Policies, Strong Pipeline and Increased Licensing Activity. The report provides an in-depth analysis on stem cell research and development in India, China, Japan, South-Korea and Singapore. The report market analysis and forecasts for CABG, LSCT, Type 1 DM, Type 2 DM, Hearticellgram, Cerecellgram, Cartistem and Cupistem. The report also provides information on trends and pipelines. In addition to this, the report covers market drivers and challenges for stem cell research market.
To Read the Complete Report with TOC Visit: http://www.marketresearchreports.biz/analysis/155690
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts.
GBI Research analysis finds the stem cell therapy market was valued at $545m in 2012, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 10% from 2012 to 2018, to attain a value of $972m in 2018. The market is poised for significant growth in the forecast period due to the anticipated launch of JCR Pharmaceuticals JR-031 (2014) in Japan and FCB Pharmicells Cerecellgram (CCG) (2015) in South Korea.
Related Report: Mobile Health (mHealth) - Enhancing Healthcare and Improving Clinical Outcomes
The research is mainly in early stages, with the majority of the molecules being in early stages of development (Phase I/II and Phase II). Phase I/II and Phase II contribute 67% of the pipeline. Stem cell research is dominated by hospitals/universities/institutions, which contribute 63% of the molecules in the pipeline. The dominance of institutional research is attributable to uncertain therapeutic outcomes in stem cell research.The major companies conducting research in India include Reliance Life Sciences and Stempeutics Research Pvt Ltd, among others. The major institutions include PGIMER and AIIMS.
Latest Report: Global SMB Web Analytics Market 2012-2016
Scope
Healthcare Report: Generic Growth Strategies - Market Driven by Impending Patent Cliff, Declining R&D Productivity and Government Initiatives to Reduce Healthcare Costs
Stem Cell Therapy Treatment for Spinal Cord Injury by Dr Alok Sharma
Stem Cell Therapy Treatment for Spinal Cord Injury by Dr Alok Sharma After Stem Cell Therapy 1) Ankle dorsiflexion movements are possible now. 2) He is able ...
By: neurogenbsi
Continued here:
Stem Cell Therapy Treatment for Spinal Cord Injury by Dr Alok Sharma - Video
Stem Cell Therapy Treatment for Autism by Dr Alok Sharma
By: neurogenbsi
See the original post here:
Stem Cell Therapy Treatment for Autism by Dr Alok Sharma - Video
Source:
Source: